127 related articles for article (PubMed ID: 6114930)
1. Effect of inflammatory disease on plasma concentrations of three beta-adrenoceptor blocking agents.
Schneider RE; Bishop H; Kendall MJ; Quarterman CP
Int J Clin Pharmacol Ther Toxicol; 1981 Apr; 19(4):158-62. PubMed ID: 6114930
[TBL] [Abstract][Full Text] [Related]
2. A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers.
Jonkers R; van Boxtel CJ; Koopmans RP; Oosterhuis B
J Pharmacol Exp Ther; 1989 Apr; 249(1):297-302. PubMed ID: 2565392
[TBL] [Abstract][Full Text] [Related]
3. Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol.
Clements JD; Jamali F
Vascul Pharmacol; 2007 Jan; 46(1):52-9. PubMed ID: 16949884
[TBL] [Abstract][Full Text] [Related]
4. Influence of endotoxin on the stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil in the rat.
Laethem ME; Belpaire FM; Wijnant P; Rosseel MT; Bogaert MG
Chirality; 1994; 6(5):405-10. PubMed ID: 8068500
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
Lemmer B
Herz; 1982 Jun; 7(3):168-78. PubMed ID: 6124492
[TBL] [Abstract][Full Text] [Related]
6. The effects of beta-adrenoceptor antagonists on proinflammatory cytokine concentrations after subarachnoid hemorrhage in rats.
Kato H; Kawaguchi M; Inoue S; Hirai K; Furuya H
Anesth Analg; 2009 Jan; 108(1):288-95. PubMed ID: 19095864
[TBL] [Abstract][Full Text] [Related]
7. Binding to serum alpha 1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation.
Belpaire FM; Bogaert MG; Mugabo P; Rosseel MT
Br J Pharmacol; 1986 Jul; 88(3):697-705. PubMed ID: 2874859
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of beta-adrenoceptor blocking agents: clinical significance of hepatic and/or renal clearance.
Borchard U
Clin Physiol Biochem; 1990; 8 Suppl 2():28-34. PubMed ID: 1982759
[TBL] [Abstract][Full Text] [Related]
9. Formation of the N-nitroso derivatives of six beta-adrenergic-blocking agents and their genotoxic effects in rat and human hepatocytes.
Robbiano L; Martelli A; Allavena A; Mazzei M; Gazzaniga GM; Brambilla G
Cancer Res; 1991 May; 51(9):2273-9. PubMed ID: 1673086
[TBL] [Abstract][Full Text] [Related]
10. The acute effect of Metoprolol upon NT-proBNP level in patients with congestive heart failure.
Zdrenghea D; Pop D; Ilea M; Bodisz G; Mălai A; Zdrenghea M
Rom J Intern Med; 2009; 47(1):35-40. PubMed ID: 19886067
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective pharmacokinetics of oxprenolol, propranolol, and verapamil: species differences and influence of endotoxin.
Laethem ME; Belpaire FM; Wijnant P; Bogaert MG
Chirality; 1995; 7(8):616-22. PubMed ID: 8593255
[TBL] [Abstract][Full Text] [Related]
12. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
Luzier AB; Killian A; Wilton JH; Wilson MF; Forrest A; Kazierad DJ
Clin Pharmacol Ther; 1999 Dec; 66(6):594-601. PubMed ID: 10613615
[TBL] [Abstract][Full Text] [Related]
13. [Effect of 3-month treatment with propranolol, oxprenolol, metoprolol and pindolol on plasma lipids and lipoproteins in patients with primary arterial hypertension].
Sznajderman M; Cybulska I; Niegowska J; Zawadzki Z; Sznajderman M
Kardiol Pol; 1985; 28(7):489-99. PubMed ID: 2868145
[No Abstract] [Full Text] [Related]
14. Concentration-effect relationship of l-propranolol and metoprolol in spontaneous hypertensive rats after exercise-induced tachycardia.
Brynne L; Karlsson MO; Paalzow LK
J Pharmacol Exp Ther; 1998 Sep; 286(3):1152-8. PubMed ID: 9732372
[TBL] [Abstract][Full Text] [Related]
15. Comparative beta-blocking potencies of acebutolol and propranolol relative to plasma drug levels.
Collett JT; Hendrickson JA; Chew CY; Shah PM; Laddu AR; Singh BN
Int J Clin Pharmacol Ther Toxicol; 1981 Nov; 19(11):473-8. PubMed ID: 6117519
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol.
Regårdh CG; Johnsson G; Jordö L; Lungborg P; Persson BA; Rönn O
J Cardiovasc Pharmacol; 1980; 2(6):715-23. PubMed ID: 6160322
[TBL] [Abstract][Full Text] [Related]
17. Thin-layer chromatographic analysis of some beta-blocking drugs in plasma.
Witek A; Przyborowski L
Acta Pol Pharm; 1997; 54(3):183-6. PubMed ID: 9511444
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.
Rigby JW; Scott AK; Hawksworth GM; Petrie JC
Br J Clin Pharmacol; 1985 Oct; 20(4):327-31. PubMed ID: 2866783
[TBL] [Abstract][Full Text] [Related]
19. Aiming for steady 24-hour plasma concentrations: a comparison of two calcium antagonist and beta-blocker combinations.
Eriksson M; Nyberg G; Lidman K; Olofsson B; Bergstrand R
Blood Press Suppl; 1993; 1():16-21. PubMed ID: 7909705
[TBL] [Abstract][Full Text] [Related]
20. Xerostomia: prevalence and pharmacotherapy. With special reference to beta-adrenoceptor antagonists.
Nederfors T
Swed Dent J Suppl; 1996; 116():1-70. PubMed ID: 8813731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
